Precision Medicine Market – Application (Diagnostics [Genetic, Biomarker Based Tests], Therapeutics [Inhibitor Drugs, Monoclonal Antibodies]), Indication (Oncology, CNS), Technology (Genomics, Bioinformatics), End-user – Global Forecast (2024 – 2032)

Precision Medicine Market Size

Precision Medicine Market size accounted for around USD 79.9 billion revenue size in 2023 and is projected to witness significant growth at 7.6% CAGR between 2024 to 2032. One of the primary drivers is the increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and diabetes. These conditions require tailored treatments, and precision medicine offers personalized approaches based on individual genetic, environmental, and lifestyle factors.
 

Further, advancements in genomics and molecular biology have also accelerated the growth of precision medicine by enabling more precise and cost-effective genetic testing. Moreover, government initiatives and funding support have also played a significant role in driving the expansion of the precision medicine market.
 

Precision medicine, also known as personalized medicine or individualized medicine, is an approach to healthcare that takes into account individual differences in genes, environment, and lifestyle when designing medical treatment plans and interventions. Rather than applying a one-size-fits-all approach, precision medicine aims to tailor medical decisions and treatments to the specific characteristics of each patient.
 

Precision Medicine Market Trends

• The expansion of the market is driven by the increasing development and availability of drugs. For instance, the number of personalized medicines on the market grew significantly, increasing from 132 to 286 between 2016 and 2020.
   
• Additionally, personalized medicines accounted for 25% of the new drugs approved by the FDA in 2019, a substantial increase from 5% in 2005. Such increasing number of drug approval and availability of precision medicine drugs, thus aids in market growth.
   
• Pharmaceutical companies are heavily investing in research and collaborations with healthcare providers and others to expand their precision medicine drug portfolios.
   
• Also, companies aiming to expand their portfolio of precision medicine drugs are partnering and collaborating with other companies. For instance, Pfizer has established a long-term collaboration with 23 and Me on genome-wide association studies to address and better understand disease mechanisms that will help the company to develop effective and efficient personalized solutions for the patients. Such strategies are anticipated to foster industry growth over the forthcoming years.
   

Precision Medicine Market Analysis

Based on application, the market is segmented into diagnostics and therapeutics. The therapeutics segment is further sub-segmented into inhibitor drugs, monoclonal antibodies, cell & gene therapy, antiviral & anti-retroviral drugs, and other therapeutics. The therapeutic segment dominated the global precision medicine market with 58.7% of market share in 2023.
 

• A growing focus on developing targeted therapies tailored to individual patient characteristics, which promise enhanced efficacy and reduced side effects compared to traditional treatments have significantly contributed to the growth of this segment.
   
• Furthermore, the rise in demand for immuno-oncology and personalized cancer therapies has been particularly impactful in driving the segmental growth.
   
• Moreover, significant investment in precision medicine research and development, supported by favorable regulatory frameworks, has fueled the growth of this segment.
   

Based on indication, the precision medicine market is categorized into oncology, CNS disorders, immunology, respiratory diseases, genetic disorders, skin diseases, and other indications. Among the indications, the oncology segment accounted for majority of market share and was valued at USD 42 billion in 2023.
 

• Cancer is one of the leading causes of morbidity and mortality worldwide, with a significant impact on public health. The prevalence of various types of cancer, such as lung, breast, colorectal, and prostate cancer, contributes to the substantial market size of the oncology segment within market.
   
• Advancements in targeted therapies have revolutionized cancer treatment paradigms, further solidifying the dominance of the oncology segment in precision medicine. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and immune checkpoint inhibitors, are designed to selectively target molecular alterations that drive cancer growth and progression.
   
• These therapies offer significant benefits over conventional chemotherapy by specifically targeting cancer cells while sparing normal cells, resulting in improved response rates and reduced toxicity. All these aforementioned factors, thus contribute to the segmental growth.
   

Based on technology, the precision medicine market is classified into genomics, bioinformatics, big data analytics, biomarker detection, high throughput screening, and other technologies. The genomics segment dominated the market and is anticipated to reach USD 37.4 billion by 2032.
 

• The genomics segment holds the highest market share in the market owing to its pivotal role in identifying genetic variations, biomarkers, and molecular signatures associated with disease.
   
• Furthermore, the expanding applications of genomics across diverse therapeutic areas, including oncology, cardiology, neurology, and rare genetic diseases, contribute to its dominance in the market.
   
• Moreover, the ongoing advancements in sequencing technologies, coupled with improved scalability, have democratized genomic profiling, making it more accessible to healthcare providers and driving its widespread adoption in precision medicine initiatives. Thereby, these factors support the growth of this segment.
   

Based on end-user, the precision medicine market is divided into hospitals, diagnostic centers, and other end-users. The hospitals segment held highest market share of 45.1% in 2023 and will experience growth at 7.6% CAGR.
 

• The hospitals segment accounted for highest market share in precision medicine due to its central role in healthcare delivery, integrated ecosystem, advanced diagnostic capabilities, and access to cutting-edge therapies.
   
• With multidisciplinary teams of healthcare professionals, hospitals offer personalized treatment plans tailored to each patient's unique medical history and genetic makeup.
   
• Overall, hospitals serve as hubs for innovation and implementation of personalized treatment approaches, driving improvements in patient care and outcomes within the market.
   

North America precision medicine market dominated the global market in 2023 and is predicted to grow at CAGR of 7.5% during the forecast timeframe.
 

• The region has well-established network of hospitals, research institutions, and diagnostic laboratories that facilitates the adoption and implementation of precision medicine approaches, thereby fostering the growth of this region.
   
• Regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, provide clear pathways for the approval and commercialization of precision medicine products and services.
   
• Additionally, reimbursement policies support the adoption of precision diagnostics and targeted therapies, ensuring access to innovative treatments for patients.
   

U.S. precision medicine market in 2023 was valued at USD 32.1 billion and is expected to grow at 7.4% CAGR over the analysis period.
 

• Increasing prevalence of cancer significantly drives the demand for precision medicines in the country. For instance, according to American Cancer Society, the estimated number of new cancer cases and cancer deaths in U.S. in 2022 were approximately 1.9 million and 609,360 respectively.
   
• Additionally, factors such as technological advancements, regulatory support, advancements in data analytics and AI, industry collaboration and investment, increased patient awareness, and integration with healthcare systems further drive the market.
   

China precision medicine market is anticipated to showcase remarkable growth over the forecast period.
 

• The Chinese government has prioritized healthcare reform and investment in precision medicine as part of its national healthcare agenda. Initiatives such as the Precision Medicine Initiative and the Healthy China 2030 plan aim to promote innovation, improve healthcare quality, and address the growing burden of chronic diseases through personalized medicine approaches.
   
• Technological progress, rising disease burden, and an expanding healthcare sector further fuel market expansion. Moreover, industry growth, increasing healthcare spending, and international collaborations are propelling the growth of market in China.
   

Germany held a significant position in global precision medicine market.
 

• Germany has emerged as a key player in the market, showcasing high growth potential. This growth is attributed to several factors, including the country's strong focus on healthcare innovation, advanced healthcare infrastructure, and robust research and development activities in the field of precision medicine.
   
• Germany's healthcare system is renowned for its high-quality care and efficient delivery, which further supports the adoption and growth of precision medicine initiatives.
   
• Additionally, the presence of leading pharmaceutical and biotechnology companies, along with a skilled workforce and favorable government policies, further contribute to the market growth.
   

Precision Medicine Market Share

The precision medicine industry is characterized by intense competition, driven by ongoing innovation, strategic partnerships, and increasing demand for personalized healthcare solutions. With advancements in technology and a growing emphasis on precision medicine in clinical practice, the market is expected to continue expanding, presenting opportunities and challenges for both established and new players.
 

Precision Medicine Market Companies

Prominent players operating in the precision medicine industry include:

• Abbott Laboratories, Inc.
• Abbvie, Inc.
• AstraZeneca plc
• bioMerieux SA
• Bristol-Myers Squibb Company
• Cepheid (Danaher Corporation)
• Eli Lilly & Company
• F. Hoffmann-La Roche
• GlaxoSmithKline plc
• Laboratory Corporation of America Holdings (Covance Inc.)
• Myriad Genetics, Inc.
• Novartis AG
• Pfizer, Inc.
• QIAGEN N.V.
• Quest Diagnostics
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• Vyant Bio, Inc. (Cancer Genetics, Inc.)
   

Precision Medicine Industry News:

• In November 2023, Bristol-Myers Squibb Company announced the FDA approval of Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of locally advanced or metastatic ros1-positive non-small cell lung cancer (NSCLC). This approval helped the company broaden its product portfolio and generate revenue.
   
• In January 2022, Pfizer announced the U.S. FDA approval of Cibinqo (abrocitinib) for adults with moderate-to-severe atopic dermatitis. This FDA approval helped the company commercialize a new drug and boost their revenue growth.
   

The precision medicine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Application

• Diagnostics
  • Genetic tests
  • Biomarker based tests
  • Esoteric tests
  • Other tests
• Therapeutics
  • Inhibitor drugs
  • Monoclonal antibodies
  • Cell & gene therapy
  • Antiviral & anti-retroviral drugs
  • Other therapeutics

Market, By Indication

• Oncology
• CNS disorders
• Immunology
• Respiratory diseases
• Genetic disorders
• Skin diseases
• Other indications

Market, By Technology

• Genomics
• Bioinformatics
• Big data analytics
• Biomarker detection
• High throughput screening
• Other technologies

Market, By End-user

• Hospitals
• Diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa